Full Product Name
FGD4 siRNA (Human)
Product Synonym Names
FRABP; ZFYVE6; FYVE. RhoGEF and PH domain-containing protein 4; Actin filament-binding protein frabin; FGD1-related F-actin-binding protein; Zinc finger FYVE domain-containing protein 6
Product Gene Name
FGD4 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q96M96
Specificity
FGD4 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human FGD4 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of FGD4 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
FGD4 sirna
siRNA to inhibit FGD4 expression using RNA interference
Applications Tested/Suitable for FGD4 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for FGD4. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001291409.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001304480.1
[Other Products]
UniProt Primary Accession #
Q96M96
[Other Products]
UniProt Secondary Accession #
Q6ULS2; Q8TCP6[Other Products]
UniProt Related Accession #
Q96M96[Other Products]
Molecular Weight
20,388 Da
NCBI Official Full Name
FYVE, RhoGEF and PH domain-containing protein 4 isoform 1
NCBI Official Synonym Full Names
FYVE, RhoGEF and PH domain containing 4
NCBI Official Symbol
FGD4 [Similar Products]
NCBI Official Synonym Symbols
CMT4H; FRABP; ZFYVE6
[Similar Products]
NCBI Protein Information
FYVE, RhoGEF and PH domain-containing protein 4
UniProt Protein Name
FYVE, RhoGEF and PH domain-containing protein 4
UniProt Synonym Protein Names
Actin filament-binding protein frabin; FGD1-related F-actin-binding protein; Zinc finger FYVE domain-containing protein 6
Protein Family
FYVE, RhoGEF and PH domain-containing protein
UniProt Gene Name
FGD4 [Similar Products]
UniProt Synonym Gene Names
FRABP; ZFYVE6 [Similar Products]
UniProt Entry Name
FGD4_HUMAN
NCBI Summary for FGD4
This gene encodes a protein that is involved in the regulation of the actin cytoskeleton and cell shape. This protein contains an actin filament-binding domain, which together with its Dbl homology domain and one of its pleckstrin homology domains, can form microspikes. This protein can activate MAPK8 independently of the actin filament-binding domain, and it is also involved in the activation of CDC42 via the exchange of bound GDP for free GTP. The activation of CDC42 also enables this protein to play a role in mediating the cellular invasion of Cryptosporidium parvum, an intracellular parasite that infects the gastrointestinal tract. Mutations in this gene can cause Charcot-Marie-Tooth disease type 4H (CMT4H), a disorder of the peripheral nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2015]
UniProt Comments for FGD4
FGD4: Activates CDC42, a member of the Ras-like family of Rho- and Rac proteins, by exchanging bound GDP for free GTP. Plays a role in regulating the actin cytoskeleton and cell shape. Activates MAPK8. Defects in FGD4 are the cause of Charcot-Marie-Tooth disease type 4H (CMT4H); also known as Charcot-Marie- Tooth disease neuropathy type 4H. CMT4H is a recessive demyelinating form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot- Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy and primary peripheral axonal neuropathy. Demyelinating CMT neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention, autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: GEFs; GEFs, Rac/Rho
Chromosomal Location of Human Ortholog: 12p11.21
Cellular Component: Golgi apparatus; ruffle; lamellipodium; cytoplasm; cytosol; actin cytoskeleton; filopodium
Molecular Function: small GTPase binding; Rho guanyl-nucleotide exchange factor activity; guanyl-nucleotide exchange factor activity; metal ion binding; actin binding
Biological Process: lamellipodium biogenesis; regulation of cell shape; regulation of small GTPase mediated signal transduction; filopodium formation; nerve growth factor receptor signaling pathway; positive regulation of apoptosis; small GTPase mediated signal transduction; microspike biogenesis; cytoskeleton organization and biogenesis; actin cytoskeleton organization and biogenesis; positive regulation of GTPase activity
Disease: Charcot-marie-tooth Disease, Type 4h
Research Articles on FGD4
1. Our results suggest that FGD4 should be screened in other early-onset CMT subtypes, regardless of the severity of the phenotype, and particularly in patients of consanguineous descent.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
